Retinal and choroidal neovascularization

Journal of Cellular Physiology

Volumn 184, Issue 3, 2000, Pages 301-310

  Campochiaro, Peter A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; FIBROBLAST GROWTH FACTOR; GENE PRODUCT; IMMUNOGLOBULIN; TYROSINE KINASE RECEPTOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; CHOROID VASCULARIZATION; ENDOTHELIUM CELL; GENE CONTROL; HUMAN; HYPEROXIA; HYPOXIA; NONHUMAN; PRIORITY JOURNAL; RETINA BLOOD VESSEL; RETINA ISCHEMIA; RETINA NEOVASCULARIZATION; REVIEW; SUBRETINAL NEOVASCULARIZATION;

ADULT; ANIMALS; ANOXIA; CHOROID; DISEASE MODELS, ANIMAL; ENDOTHELIAL GROWTH FACTORS; FEMALE; FIBROBLAST GROWTH FACTOR 2; GENE EXPRESSION REGULATION; HUMANS; HYPEROXIA; ISCHEMIA; LYMPHOKINES; MICE; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; PREGNANCY; RETINAL VESSELS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0033895534     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-4652(200009)184:3<301::AID-JCP3>3.0.CO;2-H     Document Type: Review

References (102)

1. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy
2. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization
3. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders
4. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins
5. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity
6. Growth factor localization in choroidal neovascular membranes of age-related macular degeneration
7. The gene structure of tissue inhibitor of metalloproteinases (TIMP)-3 and its inhibitory activities define the distinct TIMP gene family
8. Retinal vascularization in health and disease
9. Role of oxygen in the genesis of retrolental fibroplasia: Preliminary report
10. Angiogenesis in embryos and ischemic disease
11. Requirement of vascular integrin alpha-v beta-3 for angiogenesis
12. Oxygen sensing and molecular adaptation to hypoxia
13. Sorsby's pseudoinflammatory macular dystrophy - Sorsby's fundus dystrophy
14. Sorsby's fundus dystrophy: A light and electron microscopic study
15. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
16. Mechanisms of retinal and choroidal neovascularization
17. Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PKCbeta inhibition with LY 333531
18. Granulomatous reaction to Bruch's membrane in age-related macular degeneration
19. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning
20. A new model of choroidal neovascularization in the rat
21. Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo
22. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene
23. Role of the flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium
24. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1
25. A model of subretinal neovascularization in the pigmented rat
26. Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes
27. Involvement of integrins alpha-v beta-3 and alpha-v beta-5 in ocular neovascular diseases
28. Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia
29. Age-related macular degeneration histopathologic studies
30. Foveolar choroidal blood flow in age-related macular degeneration
31. Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization
32. Signaling vascular morphogenesis and maintenance
33. Altered distribution of basic fibroblast growth factor in diabetic retinopathy
34. High affinity immunoreactive FGF receptors in the extracellular matrix of vascular endothelial cells - Implications for the modulation of FGF-2
35. Sorsby's pseudoinflammatory macular dystrophy
36. Effects of intravitreal administration of steroids on experimental subretinal neovascularization in the subhuman primate
37. 2 homeostasis by hypoxia-inducible factor 1alpha
38. Blindness caused by diabetic retinopathy
39. Macrophages related to Bruch's membrane in age-related macular degeneration
40. A new model of subretinal neovascularization in the rabbit
41. Vision disorders in diabetes
42. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor
43. VEGF is an important stimulator in a model of choroidal neovascularization
44. Post-transcriptional regulation of vascular endothelial growth factor by hypoxia
45. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes
46. Transcription factor HIF-1- and AP2-DNA binding orchestrate angiogenic gene transcription programs during retinal neovascularization
47. Antagonists of integrin alpha-v beta-3 inhibit retinal neovascularization in a murine model
48. Localization of vascular endothelial growth factor in human retina and choroid
49. Argon laser photocoagulation for neovascular maculopathy: Five year results from randomized clinical trials
50. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis
51. Detection of vascular endothelial growth factor messenger RNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy
52. Bone morphogenetic proteins-2 and -4 are negative growth regulators in the retina and retinal pigmented epithelium
53. Visualization of a developing vasculature
54. Vasoproliferation in the neonatal dog model of oxygen-induced retinopathy
55. The mode of development of the vascular system of the retina with some observations on its significance for certain retinal diseases
56. The role of the retinal pigmented epithelium in the involution of subretinal neovascularization
57. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model
58. Extracellular matrix-integrin binding modulates secretion of angiogenic growth factors by retinal pigmented epithelial cells
59. Expression of basic fibroblast growth factor mRNA in developing choroidal neovascularization
60. Immunohistochemical distribution of basic fibroblast growth factor in experimental retinal ischemia and reperfusion in the rat
61. Transgenic mice with increased expression of vascular endothelial growth factor in the retina: A new model of intraretinal and subretinal neovascularization
62. Inhibition of capillary endothelial cell growth by pericytes and smooth muscle cells
63. Intravitreal sustained release of VEGF causes retinal neovascularization in rabbits and breakdown of the blood-retinal barrier in rabbits and primates
64. Basic fibroblast growth factor is neither necessary nor sufficient for the development of retinal neovascularization
65. Hypoxia inducible factor-1a is increased in ischemic retina: Temporal and spatial correlation with VEGF expression
66. Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization
67. Oxygen studies in retrolental figroplasia: Production of the microscopic changes of retrolental fibroplasia in experimental animals
68. Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases
69. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization
70. Vascular endothelial growth factor is a potential tumor angiogenesis factor in human gliomas in vivo
71. The receptor tyrosine kinase TIE is required for integrity and survival of vascular endothelial cells
72. Intraocular properties of AG3340, a selective matrix metalloproteinases inhibitor with antiangiogenic activity
73. Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy
74. Presumed macular choroidal watershed vascular filling, choroidal neovascularization, and systemic vascular disease in patients with age-related macular degeneration
75. Subretinal neovascularization: Natural history of an experimental model
76. Effect of intravitreal administration of indomethacin on experimental subretinal neovascularization in the subhuman primate
77. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation
78. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation
79. Dramatic inhibition of retinal and choroidal neovascularization by oral administration of a kinase inhibitor
80. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice
81. Hypoxic induction of vascular endothelial growth factor (VEGF) in human epithelial cells is mediated by increases in mRNA stability
82. Midperipheral fundus involvement in diabetic retinopathy
83. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
84. Basic fibroblast growth factor levels in the vitreous of patients with proliferative diabetic retinopathy
85. Essential role of growth hormone in ischemia-induced retinal neovascularization
86. Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor
87. A fundus dystrophy with unusual features
88. Basic fibroblast growth factor experimentally induced choroidal angiogenesis in the minipig
89. Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia
90. Requisite role of angiopoietin-1, a ligand for the Tie2 receptor, during embryonic angiogenesis
91. Targeted disruption of the FGF2 gene does not prevent choroidal neovascularization in a murine model
92. Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate
93. Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate
94. Upregulation of vascular endothelial growth factor in ischemic and non-ischemic human and experimental retinal disease
95. Increased vascular endothelial growth factor (VEGF) and transforming growth factor-beta (TGF-beta) in experimental autoimmune uveoretinitis: Upregulation of VEGF without neovascularization
96. Endothelial cell-derived basic fibroblast growth factor: Synthesis and deposition into subendothelial extracellular matrix
97. 2 tension
98. Mutations in the tissue inhibitor of metalloproteinases-3 (TIMP3) in patients with Sorsby's fundus dystrophy
99. Platelet-derived growth factor-A-induced retinal gliosis protects against ischemic retinopathy
100. Hyperoxia causes decreased expression of vascular endothelial growth factor and endothelial cell apoptosis in adult retina
101. Cell injury unmasks a latent proangiogenic phenotype in mice with increased expression of FGF2 in the retina
102. Vascular endothelial growth factor expression in choroidal neovascularization in rats